Dolobid (diflunisal) NDC 74157-009

NDC codes

FDA NDC Directory

Product NDC (as listed)74157-009Labeler and product segments. Claims need a package NDC.

Product NDC at billing width74157-0009Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
74157-009-60	74157000960	60 TABLET, FILM COATED in 1 BOTTLE (74157-009-60)Marketed from Aug 19, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dolobid
Generic name (nonproprietary): diflunisal
Active ingredients: Diflunisal — 250 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: INA Pharmaceutics Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202845
Marketing start: Aug 19, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)
Identifiers: Product ID 74157-009_4081e337-1003-6e39-e063-6294a90a4698SPL ID 4081e337-1003-6e39-e063-6294a90a4698SPL set ID 725234b2-0e23-45c3-a42d-eb4e62273f9bRxCUI 105823, 197602, 249400, 2691103UNII 7C546U4DENUPC 0374157101607, 0374157009606
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N474157000960 followed by a unit qualifier and the quantity

Package 74157-0009-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 6, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carefully consider the potential benefits and risks of Dolobid and other treatment options before deciding to use Dolobid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Dolobid is indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202845

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202845
Product	Strength	Form · route	Labeler	Product NDC
Diflunisal	Diflunisal 500 mg/1	Tablet, Film coatedOral	Chartwell RX, LLC	62135-456
Dolobiddiflunisal	Diflunisal 375 mg/1	Tablet, Film coatedOral	INA Pharmaceutics Inc	74157-101
diflunisal	Diflunisal 500 mg/1	Tablet, Film coatedOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	14539-673